SLC5A2 and type 1 diabetes mellitus: Considering the benefits that SGLT2 inhibitors bring in the treatment of T1DM, the use of these drugs in the treatment of T1DM is currently being explored, despite the possibility that they may lead to an elevated risk associated with DKA.